US20120117671A1 - Steatohepatitis-liver cancer model animal - Google Patents

Steatohepatitis-liver cancer model animal Download PDF

Info

Publication number
US20120117671A1
US20120117671A1 US13/319,851 US200913319851A US2012117671A1 US 20120117671 A1 US20120117671 A1 US 20120117671A1 US 200913319851 A US200913319851 A US 200913319851A US 2012117671 A1 US2012117671 A1 US 2012117671A1
Authority
US
United States
Prior art keywords
human animal
liver cancer
steatohepatitis
administering
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/319,851
Other languages
English (en)
Inventor
Hiroyuki Yoneyama
Masato Fujii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stelic Institute and Co Inc
Original Assignee
Stelic Institute and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43528923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20120117671(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stelic Institute and Co Inc filed Critical Stelic Institute and Co Inc
Assigned to STELIC INSTITUTE OF REGENERATIVE MEDICINE, STELIC INSTITUTE & CO. reassignment STELIC INSTITUTE OF REGENERATIVE MEDICINE, STELIC INSTITUTE & CO. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FUJII, MASATO, YONEYAMA, HIROYUKI
Publication of US20120117671A1 publication Critical patent/US20120117671A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/25—Animals on a special diet
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases

Definitions

  • the present invention relates to steatohepatitis/liver cancer model animals, and uses thereof.
  • non-alcoholic fatty liver disease was believed to be a benign disease that does not progress. However, it was revealed that even non-drinkers develop inflammation similar to alcoholic hepatitis and show hepatic fibrosis histology, and now the non-alcoholic fatty liver disease is known as a disease with poor prognosis.
  • metabolic syndromes due to obesity, diabetes, or the like have been drawing attention in recent years. It is becoming a common view that nonalcoholic steatohepatitis (NASH) is one of such syndromes.
  • NASH nonalcoholic steatohepatitis
  • the mechanism remains unclear, and effective methods and/or agents for treating NASH have not been established. This is partly because NASH is due to human lifestyle-related diseases, and thus appropriate experimental animals have not been established.
  • Non-patent Document 1 leptin receptor-deficient mice
  • Non-patent Document 2 hepatocyte-specific Pten-deficient mice
  • Non-patent Document 3 retinoic acid receptor a dominant-negative transgenic mice
  • mice induced with a special diet such as a methionine/choline-deficient diet
  • the human pathogenesis differs from that in the genetically-modified mice in which a single-gene mutation is responsible for the development and progression of the pathological condition, and is unlikely to be due to only the intake of a particular nutrient. Furthermore, insulin resistance and hepatic fibrosis cannot be simultaneously monitored in these mice. Furthermore, the ALT, an index in serobiochemical analysis, is only slightly elevated in mice that develop fibrosis, and therefore several mouse tissue slices are required to assess their pathological condition. Conversely, the pathological condition is assumed to be different from that of human because ALT is elevated to a markedly high level. Furthermore, the pathological condition recovers spontaneously after treatment. This makes it difficult to test and assess drugs for their efficacy. Thus, for developing methods and agents for treating NASH, it is desirable to establish an experimental animal model that is compatible with the human clinical condition.
  • An objective of the present invention is to provide steatohepatitis model animals and liver cancer model animals that exhibit pathological findings similar to those of humans, and uses thereof. More specifically, an objective of the present invention is to provide techniques for producing model animals that develop into fatty liver, steatohepatitis, hepatic fibrosis, liver cirrhosis, and liver cancer from insulin resistance.
  • the present inventors conducted dedicated studies to achieve the above-described objectives.
  • the present inventors induced insulin resistance by administering an agent for inducing organ inflammation, and induced fatty liver in mice by feeding them with a high fat diet.
  • the present inventors successfully developed steatohepatitis in mice.
  • a detailed observation of the mice revealed the following pathological findings:
  • the above-described pathological findings are characteristic of human nonalcoholic steatohepatitis (NASH). Specifically, by using the above-described method, the present inventors for the first time successfully produced mice that exhibit similar pathological findings as those of human NASH.
  • NASH nonalcoholic steatohepatitis
  • the NASH animal model produced by the present inventors is different from conventional animal models in the following points:
  • the animal model of the present invention is characteristic in that it is produced without genetic modification. Furthermore, the model animals of the present invention unfailingly (100%) develop a pathological condition similar to the progression and prognosis of human NASH at a constant time course, and are the first model animals that exhibit the same course of progression of pathological condition in human. In addition, the model animals of the present invention have a remarkably beneficial effect in that all of insulin resistance, fatty liver, steatohepatitis, hepatic fibrosis, and liver cirrhosis can be observed at the same time.
  • the present inventors newly found that the above-described NASH model animals develop liver cancer following liver cirrhosis as they continue the rearing. This is the same change of pathological condition observed in humans.
  • the animals prepared by the methods of the present invention are very useful as model animals of human liver cancer.
  • Human liver cancer causes the liver surface to bulge.
  • conventional model animals for liver cancer which are prepared by administering a chemical substance, develop liver cancer that does not cause bulging of the liver surface.
  • model animals of the present invention which are prepared without genetic modification and drug administration, exhibit bulging of the liver surface in a fashion similar to the case of human liver cancer.
  • the model of the present invention is a model much closer to human liver cancer.
  • liver cirrhosis is not developed by administering chemical substances, while model animals of the present invention develop massive type cord-like liver cell carcinoma.
  • infiltration of inflammatory cells and development of liver cancer caused by cirrhosis to displace normal liver cells are observed in the model animals of the present invention.
  • liver cancer is macrovesicular fatty liver which shows a pathological condition very similar to that of human NASH.
  • the liver cancer develops from hepatic fibrosis and liver cirrhosis.
  • the animal model of the present invention is very useful, as it has not been reported previously.
  • the present inventors successfully produced model animals for steatohepatitis and liver cancer which show similar pathological findings to those of human, and thereby completed the present invention.
  • model animals it is possible to efficiently screen for substances for treating or preventing diseases, and effectively evaluate the efficacy of medicinal substances.
  • the present invention relates to model animals which develop into fatty liver, steatohepatitis, hepatic fibrosis, cirrhosis, and liver cancer from insulin resistance, and more specifically, the present invention provides:
  • mice To produce experimental animals that develop pathological conditions similar to those of humans, insulin resistance was induced in mice, and fatty liver was induced by feeding them with a high fat diet.
  • NAFLD Activity Score (NAS; reference: “Kleiner D E et al., Hepatology. 2005 June; 41(6): 1313-21”) was calculated to assess the pathological features in detail.
  • Model animals of the present invention can also be assessed for NASH by using the same NAFLD Activity Score as for human. Thus, the model animals of the present invention are very useful as NASH model animals.
  • the present inventors successfully produced steatohepatitis model animals (for example, NASH model animals) and liver cancer model animals that show pathological findings similar to those of humans.
  • the present invention provides simple techniques for stably producing animals that develop at an early stage a pathological condition similar to human NASH, which leads to fatty liver, steatohepatitis, hepatic fibrosis, and liver cirrhosis, followed by spontaneous development of liver cancer as a result of progression of the pathological condition, by inducing insulin resistance in experimental animals such as mice, and loading them with a high fat diet.
  • diabetic disorders can also be simultaneously observed in the animals.
  • the present invention also provides techniques for producing experimental animals that enable the pathological conditions of metabolic syndrome to be observed at the same time.
  • the pathological condition does not develop uniformly with aging. It is necessary to monitor the pathological condition of the mice to accurately assess the disease state of NASH, which makes the experiments cumbersome and complicated. Furthermore, the pathological lesions are not always irreversible. This has made the efficacy assessment difficult (Horie Y et al., J din Invest 113: 1774-1783, 2004; Yanagitani A et al., Hepatology 40: 366-375, 2004; Anstee Q M et al., Int J Exp Path 87: 1-16, 2006). Meanwhile, in the model animals of the present invention, the period leading to the mature pathological condition is constant and its progression is irreversible. Thus, the model animals of the present invention can be used to solve the above-described problems.
  • the model animals of the present invention can be used in preclinical tests for various therapeutic agents, and are very useful in developing agents and searching for therapeutic targets.
  • FIG. 1 shows a result of serobiochemical test in mice of the present invention.
  • FIG. 2 shows in photographs a result of fat staining of liver from a mouse of the present invention.
  • FIG. 3 shows in photographs a result of immunostaining of liver from a mouse of the present invention.
  • FIG. 4 shows in photographs a result of HE staining of liver from a 20-week-old mouse of the present invention.
  • FIG. 5 shows a result of HE staining of liver from C57BL/6J in photographs and the NAFLD Activity Score in a graph.
  • FIG. 6 shows in photographs a result of F4/80 immunostaining of pancreas and adipose tissue from C57BL/6J.
  • FIG. 7 shows in photographs a result of immunostaining of F4/80 and ER-TR7 of 8-week-old BALB/c and C3H/HeN mice.
  • FIG. 8 shows photographs of liver cancer in 20-week-old C3H/HeN.
  • FIG. 9 shows in photographs reproducible results of NASH model mice reared with other high fat diets.
  • FIG. 10 shows in photographs and graphs results of pharmacological tests using the NASH model mice. 1 shows the result of histological analysis in photographs. 2 shows the result of gene expression analysis in photographs.
  • FIG. 11 shows the onset of diabetic complications in photographs. 1 shows diabetic nephropathy in photographs, while 2 shows diabetic retinopathy (immunostaining images of new blood vessels; CD31) in photographs.
  • the present invention relates to steatohepatitis model animals produced by inducing insulin resistance.
  • the present invention provides steatohepatitis model animals (herein sometimes referred to as “model animals of the present invention”) prepared by administering agents for inducing organ inflammation.
  • Model animals of the present invention are prepared by administering to experimental animals agents for inducing organ inflammation and then preferably feeding them with high fat diets.
  • Animals to be used in the present invention are not particularly limited, as long as they are commonly used as experimental animals. Such animals typically include non-human animals, preferably non-human vertebrates, more preferably non-human mammals, and still more preferably rodents. Examples of animals that can be used to prepare model animals of the present invention specifically include mice, rats, rabbits, dogs, chickens, and monkeys (such animals are sometimes also referred to simply as “experimental animals”).
  • the genetic background of the animals to be used to produce model animals of the present invention is not particularly limited; and it is possible to use animals with any genetic background. In general, wild-type animals can be preferably used.
  • the agents for inducing organ inflammation are not particularly limited, as long as they have an activity of directly or indirectly inducing inflammation in various organs.
  • Organs for inducing inflammation include, for example, pancreas, adipose tissues, and muscle tissues.
  • the agents for inducing organ inflammation of the present invention also include agents that directly or indirectly induce inflammation in the peripheral tissues.
  • the agents for inducing organ inflammation of the present invention preferably include N-acetyl- ⁇ -D-glucosaminidase inhibitors.
  • model animals of the present invention are produced by administering N-acetyl- ⁇ -D-glucosaminidase inhibitors to the above-described experimental animals.
  • inhibitors include, for example, streptozotocin and Pugnac.
  • nucleic acids having an activity of inhibiting N-acetyl- ⁇ -D-glucosaminidase can also be used as an agent of the present invention.
  • nucleic acids include, for example, siRNAs that suppress the expression of the O-G1cNAcase gene (GenBank accession No. NM — 023799.3), antisenses of the gene, and ribozymes that target the gene.
  • the dosage form of the agents for inducing organ inflammation is not particularly limited.
  • the dosage form includes, for example, subcutaneous administration (subcutaneous injection, etc.), intravenous administration, oral administration, and intraperitoneal administration.
  • the dose of the agent to be administered is not limited, and is typically 50 to 500 ⁇ g, preferably 100 to 300 ⁇ g, and more preferably 200 ⁇ g when the agent is streptozotocin.
  • the timing for administering the agent is as follows.
  • the agent is typically administered one to five days after birth (neonatal period, preferably one to five days old, and more preferably two days old), and preferably two days after birth.
  • insulin resistance can be induced by administering the agents.
  • the animals are reared to produce model animals of the present invention.
  • the animals are preferably fed with a high fat diet.
  • Such high fat diets include various general animal diets that are commercially available.
  • the major ingredients of the above-described high fat diets include, for example, crude fat, crude protein, crude fiber, crude ash, nitrogen-free extract, and water.
  • the high fat diets of the present invention are not particularly limited; however, the content of crude fat is 20% or more, and preferably 30% or more; and the ratio of fat-derived calories to total calories is typically 50% or more, and preferably 60% or more.
  • Ingredients to be formulated into the high fat diets include, for example, powdered beef tallow, milk casein, powdered egg white, L-cystine, safflower oil, crystalline cellulose, maltodextrin, lactose, and sucrose. These substances are shown as an example of ingredients of the high fat diets, and are not necessarily contained in the diets.
  • high fat diets include, but are not limited to, for example, those that have a higher content of crude fat (for example, higher by about 30% or more) than normal diets.
  • An example of such high fat diets include those commercially available as diets for laboratory animals, such as High Fat Diet32 (CLEA Japan Inc.) and D12492 (Research Diets).
  • the above-described high fat diet feeding begins typically at the age of 2 to 6 weeks, preferably 3 to 5 weeks, and more preferably 4 weeks.
  • the amount of high fat diet given each time is about 3 to 6 g.
  • mice are preferably fed with the high fat diet for one week or more.
  • Those skilled in the art can appropriately regulate (adjust) the amount of high fat diet depending on the type, size, weight, or such of the experimental animals to be used.
  • Fatty liver can be induced by feeding them with a high fat diet.
  • the present invention provides steatohepatitis model animals, which comprise the step of inducing fatty liver by administering to the animals agents for inducing organ inflammation and by feeding them with a high fat diet.
  • Animals produced by the above-described method develop symptoms of steatohepatitis and are useful as steatohepatitis model animals.
  • the model animals of the present invention have the characteristic of simultaneously developing pathological conditions that are observed in animals prepared by the methods of the present invention. It is preferred that the model animals simultaneously develop insulin resistance and/or hepatic fibrosis. However, such pathological conditions are not limited to these examples.
  • the model animals of the present invention are characteristic in that the pathological conditions of metabolic syndrome can be observed at the same time, since diabetic disorders (diabetic nephritis, retinopathy, hyperlipidemia, and arteriosclerosis) can be observed simultaneously in model animals of the present invention.
  • diabetic disorders diabetic nephritis, retinopathy, hyperlipidemia, and arteriosclerosis
  • model animals of the present invention have the characteristic that pathological condition does not recover spontaneously, the animals can be suitably used in testing and assessing drug efficacy.
  • the above-described steatohepatitis is nonalcoholic hepatitis (NASH).
  • NASH nonalcoholic hepatitis
  • the present invention provides nonalcoholic hepatitis (NASH) model animals, which are prepared by administering agents for inducing organ inflammation. The animals steadily develop in a constant time course pathological conditions with similar progression and prognosis to those of human NASH.
  • nonalcoholic hepatitis model animals of the present invention have at least one (preferably, all) of the following pathological findings:
  • model animals of the present invention are structurally characterized by the above-described pathological morphologies.
  • steatohepatitis model animals of the present invention developed liver cirrhosis which led to liver cancer.
  • steatohepatitis model animals of the present invention are also useful, for example, as animals (starting materials) for producing liver cirrhosis model animals or liver cancer model animals
  • the present invention provides materials for preparing liver cirrhosis or liver cancer model animals, which comprise steatohepatitis model animals of the present invention.
  • the present invention provides methods for producing steatohepatitis model animals, which comprise the step of administering agents for inducing organ inflammation to non-human animals
  • substances for treating or preventing steatohepatitis can be screened by using model animals of the present invention.
  • the present invention provides methods of screening for substances for treating or preventing steatohepatitis, which comprise the steps of:
  • Test substances to be used in these methods are not particularly limited.
  • such substances include single compounds such as natural compounds, organic compounds, inorganic compounds, proteins, and peptides, as well as compound libraries, expression products of gene libraries, cell extracts, cell culture supernatants, products of fermenting microorganisms, extracts of marine organisms, and plant extracts, but are not limited thereto.
  • test substances or medicinal substances of the present invention are not particularly limited; however, they can be administered, for example, orally or by injection.
  • a test substance is a protein
  • a viral vector carrying a gene encoding the protein may be constructed and can be introduced into model animals of the present invention using their infectability.
  • the ameliorating effect on steatohepatitis can be evaluated by determining whether steatohepatitis is ameliorated by assessing the pathological findings of the model animals.
  • the pathological findings of steatohepatitis include, for example, the above-described pathological findings (pathological morphologies).
  • pathological morphologies pathological morphologies
  • “amelioration” means that the symptoms of steatohepatitis are alleviated or restored to normal.
  • pathological findings described herein those skilled in the art can appropriately evaluate whether the symptoms of steatohepatitis are ameliorated in the model animals.
  • substances that produce the ameliorating effect in the step of (b) above can be selected as substances for treating or preventing steatohepatitis.
  • the present invention provides methods for evaluating the efficacy of medicinal substances in ameliorating steatohepatitis, which comprise the steps of:
  • medicinal substances that can be evaluated for efficacy by the above-described methods is not particularly limited; and such medicinal substances include, for example, various known pharmaceutical agents (low-molecular-weight compounds, proteins, nucleic acids, or such).
  • model animals of the present invention are characterized in showing diabetic disorders (diabetic nephritis, retinopathy, or such) which develop as a complication of diabetes, simultaneously in conjunction with steatohepatitis.
  • diabetic disorders diabetic nephritis, retinopathy, or such
  • model animals of the present invention are useful as diabetes model animals.
  • the present invention provides diabetes model non-human animals prepared by administering agents for inducing organ inflammation.
  • Agents for treating or preventing diabetic disorders can be developed by using diabetes model animals of the present invention.
  • candidate compounds for treating or preventing diabetic disorders can be screened by administering test substances to diabetes model animals of the present invention, and evaluating their ameliorating effect on diabetic disorders.
  • the present invention provides methods of screening for substance for treating or preventing diabetic disorders, which comprise the steps of:
  • Model animals of the present invention develop diabetic complications and are thus very useful as model animals, because risks such as side effects discovered at clinical trials can be evaluated at earlier stages by using the model animals.
  • the present invention provides methods for evaluating the side effects risks of pharmaceutical agents by using the diabetes model animals of the present invention.
  • the present invention relates to methods for evaluating the risk of side effects of pharmaceutical agents for treating or preventing diabetic disorders, which comprise the steps of:
  • the present inventors for the first time discovered that as the rearing continues, the above-described steatohepatitis model animals of the present invention develop liver cirrhosis which leads to liver cancer.
  • the present invention provides liver cirrhosis model animals and liver cancer model animals which are prepared by continuing to rear the above-described steatohepatitis model animals.
  • the present invention relates to liver cancer model animals which are prepared by continuing the rearing of steatohepatitis model animals prepared by administering agents for inducing organ inflammation.
  • liver cancer model animals of the present invention subsequently develop liver cirrhosis.
  • Liver cancer model animals can be produced by further rearing of the animals.
  • the period of rearing after liver cirrhosis has developed is typically, for example, 2 to 20 weeks or more, and preferably 10 weeks or more, when the experimental animal is mouse.
  • Liver cancer model animals of the present invention are structurally characterized, for example, by at least one (preferably, all) selected from the following pathological findings (pathological morphologies):
  • Liver cancer model animals having the above-described characteristics exhibit the pathological morphologies described above, and thus are structurally different from conventional liver cancer model animals prepared by administering chemical substances (carcinogenic substances).
  • Substances for treating or preventing liver cancer can be selected by using the above-described liver cancer model animals of the present invention.
  • the above-described methods of the present invention includes methods of screening for substances for treating or preventing liver cancer, which comprise the steps of:
  • the therapeutic effect can be appropriately evaluated, for example, using as an indicator the above-described pathological findings of liver cancer.
  • the test substance is judged to have therapeutic effect on liver cancer.
  • the methods include, for example, those comprising the steps of:
  • Pancreatic inflammation was induced in male mice of C57BL6J/JcL, BALB/cByJJcl, and C3H/HeNJcl (CLEA Japan Inc.) two days after birth with cytotoxicity specific to N-Acetyl-beta-D-glucosaminidase (O-GlcNAcase) in pancreatic ⁇ cells (for example, by subcutaneously administering 10 mg/ml streptozotocin (SIGMA) at 20 ⁇ l/head).
  • SIGMA streptozotocin
  • the mice were reared with a CE-2 diet (CLEA Japan Inc.) and sterile water until four weeks old, and ablactated when they reached the age of four weeks. Then, the mice were reared until 20 weeks old with sterile water and High Fat Diet (CLEA Japan Inc.) or D12492 (Research Diets), which have a higher crude fat content (or by about 30% or more) than normal diet.
  • mice of different ages were fasted for 24 hours, they were sacrificed under ether anesthesia, and blood was collected. Each organ was frozen in OCT compound (Sakura Fine Technical), and then sliced into sections for pathological analysis. A serobiochemical test showed that the levels of fasting blood glucose, alanine aminotransferase (ALT), and neutral fat were all higher in this model as compared to the group of normal animals. Thus, the model animals developed insulin resistance and hyperlipemia ( FIG. 1 ). Histologically, severe fatty liver with liver cell ballooning was observed at the age of five weeks. Fat was almost completely eliminated from the liver at the age of eight weeks, and thus the progression of histopathological condition was very similar to that of human burned-out NASH ( FIG. 2 ).
  • the pathogenesis of NASH in this mouse model is that pancreatic inflammation triggers chronic inflammation in peripheral tissues such as liver and adipose tissues; insulin resistance develops; and persistent systemic inflammation leads to fatty liver ( FIG. 6 ). Then, the regenerating nodules enlarged as the mice age. Infiltration of inflammatory cells, increase of atypical hepatocytes, and development of cancer to displace normal liver cells were observed at the age of 20 weeks ( FIG. 4 ). Moreover, lesions that are histologically consistent with NASH lesion which leads to liver cancer can also be developed in mice of other lines ( FIGS. 7 and 8 ). NASH lesions were reproducible even if the type of high fat diet was changed ( FIG. 9 ).
  • angiotensin receptor antagonist which is an antihypertensive agent
  • ARB angiotensin receptor antagonist
  • adipose tissue inflammation is also induced at the same time and this potentiates insulin resistance.
  • the resulting persistent chronic hyperglycemia causes microangiopathy and such, leading to diabetic complications (diabetic nephropathy, retinopathy, and neuropathy).
  • diabetic complications diabetic nephropathy, retinopathy, and neuropathy.
  • pathological lesions in other organs were studied in detail.
  • glomerular and interstitial fibrosis which are characterized by accumulation of inflammatory macrophages and fibroblasts within and around renal glomeruli were observed at the age of ten weeks, and thus the animals developed diabetic nephropathy ( FIG. 11 ).
  • mice of the present invention neovascular blood hyperplasia was observed in the retina, suggesting that the mice developed diabetic retinopathy ( FIG. 11 ).
  • the present invention provides NASH model animals which develop fatty liver leading to liver cancer.
  • the use of such model animals facilitates the analysis of pathogenesis and pathological condition of human NASH, and development of techniques and agents for treating human NASH.
  • the causes of fat accumulation in the liver include alcohol, obesity, diabetes, lipid metabolism abnormality, pharmaceutical agents, and severe malnutrition.
  • the causes are roughly categorized as alcoholic and nonalcoholic.
  • Alcoholic fatty liver leads to hepatitis, liver fibrosis, and liver cirrhosis.
  • nonalcoholic fatty liver has been believed to be a pathological condition that does not progress.
  • nonalcoholic fatty liver is a high-incidence disease next to type C hepatitis and alcoholic hepatitis in Europe and the United States.
  • the pathological condition was reported to progress into liver cirrhosis and finally liver cancer, which drew attention to the disease.
  • the model of the present invention is highly similar to the pathological condition of human NASH in terms of disease progression, and can be used to determine the stage for analyzing the phases of insulin resistance, fatty liver, steatohepatitis, liver fibrosis, and liver cirrhosis, depending on the subject to be treated. Furthermore, by searching for pathogenic factors involved in the progression of each phase, the present invention can also contribute to the development of completely new methods or agents for treating human NASH, hepatic fibrosis, and liver cirrhosis, as well as biomarkers for the diseases. In addition, the present invention is applicable to evaluate pharmacokinetics in NASH lesions. Moreover, the model of the present invention finally leads to liver cancer. Thus, the present invention enables the screening for cancer-suppressing agents or such, investigation of onset mechanism for liver cancer, and pharmaceuticals that target molecules in development of liver cancer.
  • diabetic disorders can also be analyzed at the same time.
  • the present invention is expected to greatly contribute to the development of methods and agents for liver diseases, elucidation of the relationships among systemic pathological conditions in a subject animal, as well as development of therapeutic methods/agents and biomarkers.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
US13/319,851 2009-07-31 2009-07-31 Steatohepatitis-liver cancer model animal Abandoned US20120117671A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2009/063675 WO2011013247A1 (ja) 2009-07-31 2009-07-31 脂肪性肝炎－肝癌モデル動物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/063675 A-371-Of-International WO2011013247A1 (ja) 2009-07-31 2009-07-31 脂肪性肝炎－肝癌モデル動物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/191,942 Continuation US9596834B2 (en) 2009-07-31 2014-02-27 Steatohepatitis-liver cancer model animal

Publications (1)

Publication Number Publication Date
US20120117671A1 true US20120117671A1 (en) 2012-05-10

Family

ID=43528923

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/319,851 Abandoned US20120117671A1 (en) 2009-07-31 2009-07-31 Steatohepatitis-liver cancer model animal
US14/191,942 Active US9596834B2 (en) 2009-07-31 2014-02-27 Steatohepatitis-liver cancer model animal

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/191,942 Active US9596834B2 (en) 2009-07-31 2014-02-27 Steatohepatitis-liver cancer model animal

Country Status (9)

Country Link
US (2) US20120117671A1 (zh)
EP (1) EP2460403B1 (zh)
JP (1) JP5337245B2 (zh)
KR (2) KR20120039742A (zh)
CN (1) CN102548393B (zh)
DK (1) DK2460403T3 (zh)
ES (1) ES2738101T3 (zh)
PL (1) PL2460403T3 (zh)
WO (1) WO2011013247A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017004454A1 (en) * 2015-06-30 2017-01-05 Eiger Group International, Inc. Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
US11612149B2 (en) 2015-07-10 2023-03-28 Chugai Seiyaku Kabushiki Kaisha Non-human animal having human CD3 gene substituted for endogenous CD3 gene
US11793180B2 (en) * 2016-08-22 2023-10-24 Chugai Seiyaku Kabushiki Kaisha Gene-modified mouse expressing human GPC3 polypeptide
US11937587B2 (en) 2014-11-24 2024-03-26 Regeneron Pharmaceuticals, Inc. Non-human animals expressing humanized CD3 complex

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106659722A (zh) * 2014-04-18 2017-05-10 株式会社Lg生命科学 用于预防或治疗脂肪肝疾病的组合物
CN104737985A (zh) * 2015-03-03 2015-07-01 河北工程大学 一种小鼠模拟运输应激模型的建立方法
CN105557623A (zh) * 2015-12-02 2016-05-11 南京凯斯艾生物科技有限公司 一种非酒精性脂肪性肝炎转化成肝癌的实验动物模型
SG11201807448WA (en) * 2016-03-01 2018-09-27 Smc Global Asset Inc Non-human animals exhibiting degenerative symptom attributed to protein aggregation
WO2019038908A1 (ja) 2017-08-25 2019-02-28 学校法人 日本歯科大学 非アルコール性脂肪性肝疾患の非ヒトモデル動物
CN111248149B (zh) * 2018-12-03 2022-01-28 凯斯艾生物科技（苏州）有限公司 一种糖尿病伴随重度非酒精性脂肪性肝炎小鼠模型的构建方法
CN110338150A (zh) * 2019-08-11 2019-10-18 江苏珂玛麒生物科技有限公司 一种儿童及青少年肥胖性肾病的动物模型、制备方法、及应用
US20220117206A1 (en) * 2020-10-19 2022-04-21 University Of Florida Research Foundation, Incorporated Mouse Model of Alcohol-induced Liver Cancer
CN112674028B (zh) * 2020-12-30 2022-06-28 汉姆德(宁波)智能医疗科技有限公司 促诱癌剂诱发动物癌症模型建立的方法
KR20220158637A (ko) 2021-05-24 2022-12-01 연세대학교 산학협력단 비알코올성 지방간 인공 조직 모델
KR20220168167A (ko) 2021-06-15 2022-12-22 연세대학교 산학협력단 다중 장기 모델

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070265323A1 (en) * 2001-06-12 2007-11-15 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000270713A (ja) * 1999-03-23 2000-10-03 Kennetto:Kk 糖尿病態モデル動物及びその製造方法並びに糖尿病態モデル動物の選定方法
JP4271925B2 (ja) * 2002-10-23 2009-06-03 株式会社クレハ 糖尿病モデル動物及びその作製方法
US20110027248A1 (en) 2007-12-27 2011-02-03 Hiroyuki Yoneyama Sugar Chain-Related Gene and Use Thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070265323A1 (en) * 2001-06-12 2007-11-15 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kunjathoor et al. J. Clin. Invest. 1996. 97:1767-1773 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11937587B2 (en) 2014-11-24 2024-03-26 Regeneron Pharmaceuticals, Inc. Non-human animals expressing humanized CD3 complex
WO2017004454A1 (en) * 2015-06-30 2017-01-05 Eiger Group International, Inc. Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
US10688083B2 (en) 2015-06-30 2020-06-23 Eiger Group International, Inc. Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
US11612149B2 (en) 2015-07-10 2023-03-28 Chugai Seiyaku Kabushiki Kaisha Non-human animal having human CD3 gene substituted for endogenous CD3 gene
US11793180B2 (en) * 2016-08-22 2023-10-24 Chugai Seiyaku Kabushiki Kaisha Gene-modified mouse expressing human GPC3 polypeptide

Also Published As

Publication number Publication date
PL2460403T3 (pl) 2019-11-29
EP2460403B1 (en) 2019-05-22
US20140178306A1 (en) 2014-06-26
EP2460403A4 (en) 2013-11-20
KR20160048225A (ko) 2016-05-03
JP5337245B2 (ja) 2013-11-06
DK2460403T3 (da) 2019-08-19
CN102548393A (zh) 2012-07-04
JPWO2011013247A1 (ja) 2013-01-07
CN102548393B (zh) 2015-06-03
US9596834B2 (en) 2017-03-21
KR20120039742A (ko) 2012-04-25
WO2011013247A1 (ja) 2011-02-03
KR101761078B1 (ko) 2017-07-24
EP2460403A1 (en) 2012-06-06
ES2738101T3 (es) 2020-01-20

Similar Documents

Publication Publication Date Title
US9596834B2 (en) Steatohepatitis-liver cancer model animal
Liedtke et al. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects
Guan et al. GLP-2 receptor in POMC neurons suppresses feeding behavior and gastric motility
Abreu-Vieira et al. Cidea improves the metabolic profile through expansion of adipose tissue
McClean et al. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet
Musso et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis
Denk et al. Animal models of NAFLD from the pathologist's point of view
Bjursell et al. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet
Isken et al. Impairment of fat oxidation under high-vs. low-glycemic index diet occurs before the development of an obese phenotype
Zhuhua et al. A novel mice model of metabolic syndrome: the high-fat-high-fructose diet-fed ICR mice
Geberhiwot et al. Relative adipose tissue failure in Alström syndrome drives obesity-induced insulin resistance
Arriga et al. Peroxiredoxin 6 is a key antioxidant enzyme in modulating the link between glycemic and lipogenic metabolism
Basseri et al. Loss of TDAG51 results in mature-onset obesity, hepatic steatosis, and insulin resistance by regulating lipogenesis
JP6670556B2 (ja) 非アルコール性脂肪肝炎モデル動物の製造方法
JP2012080830A (ja) ヒト非アルコール性脂肪性肝炎（ｎａｓｈ）の非ヒトモデル動物
Engel et al. Rodent models of diet-induced type 2 diabetes mellitus: A literature review and selection guide
US20220288053A1 (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
Chen et al. Tetramethylpyrazine reduces inflammation in the livers of mice fed a high fat diet
Zhao et al. Type 2 diabetes mellitus non-genetic Rhesus monkey model induced by high fat and high sucrose diet
Obydah et al. Effect of vanillic acid and exercise training on fatty liver and insulin resistance in rats: Possible role of fibroblast growth factor 21 and autophagy
Tudurí et al. Partial ablation of leptin signaling in mouse pancreatic α-cells does not alter either glucose or lipid homeostasis
JP2009178143A (ja) 脂肪性肝炎−肝癌モデル動物
US20110044909A1 (en) Animal model for diabetes
Kong et al. Kill two birds with one stone: making multi-transgenic pre-diabetes mouse models through insulin resistance and pancreatic apoptosis pathogenesis
KR20110116518A (ko) 제1형 및 제2형의 혼합형 당뇨질환 동물모델 및 이의 제조방법

Legal Events

Date Code Title Description
AS Assignment

Owner name: STELIC INSTITUTE OF REGENERATIVE MEDICINE, STELIC

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YONEYAMA, HIROYUKI;FUJII, MASATO;REEL/FRAME:027616/0713

Effective date: 20120127

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION